Transmedics Group 

€61.70
2161
+€1.40+2.32% Monday 13:41

Statistics

Day High
62.28
Day Low
61.48
52W High
70.08
52W Low
58.02
Volume
285
Avg. Volume
-
Mkt Cap
2.13B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q1 2026
Next
0.26
0.34
0.43
0.51
Expected EPS
0.4590900335
Actual EPS
N/A

Financials

31.17%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
525.73MRevenue
163.89MNet Income

Analyst Ratings

102.44Average Price Target
The highest estimate is 132.79.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8T8.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap106.49B
Medtronic offers a range of medical devices and technologies that can compete with TransMedics' organ transplantation solutions.
Abbott Laboratories
ABT
Mkt Cap166.17B
Abbott Laboratories provides a broad portfolio of medical devices, including those for cardiovascular and neuromodulation, which can be seen as indirect competitors to TransMedics' offerings.
Boston Scientific
BSX
Mkt Cap67.09B
Boston Scientific Corporation competes in the medical devices sector, offering products that could be used in cardiovascular procedures, potentially competing with TransMedics' organ preservation technologies.
Stryker
SYK
Mkt Cap125.18B
Stryker Corporation specializes in medical technologies, including surgical equipment and neurotechnology products, which could be used in procedures that compete with TransMedics' transplantation solutions.
Edwards Lifesciences
EW
Mkt Cap54.34B
Edwards Lifesciences Corporation focuses on patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring, which could indirectly compete with TransMedics' technologies.
Zimmer Biomet
ZBH
Mkt Cap18.01B
Zimmer Biomet Holdings, Inc. offers musculoskeletal healthcare solutions, which could be seen as competing in the broader medical devices market against TransMedics' organ preservation and transplantation technologies.
Intuitive Surgical
ISRG
Mkt Cap150.88B
Intuitive Surgical, Inc. develops, manufactures, and markets robotic products for minimally invasive surgery, which could compete with TransMedics in the surgical and transplantation market.
Baxter International
BAX
Mkt Cap11.7B
Baxter International Inc. provides a portfolio of healthcare products, including renal and hospital products, which could compete with TransMedics' organ preservation solutions.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson operates in the healthcare field with a broad range of products. Its medical devices segment could indirectly compete with TransMedics in various areas, including surgical technologies.

About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Show more...
CEO
ISIN
US89377M1099
WKN
000A2PH5P

Listings

0 Comments

Share your thoughts

FAQ

What is Transmedics Group stock price today?
The current price of 8T8.XETRA is €61.70 EUR — it has increased by +2.32% in the past 24 hours. Watch Transmedics Group stock price performance more closely on the chart.
What is Transmedics Group stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Transmedics Group stocks are traded under the ticker 8T8.XETRA.
What is Transmedics Group market cap?
Today Transmedics Group has the market capitalization of 2.13B
When is the next Transmedics Group earnings date?
Transmedics Group is going to release the next earnings report on July 30, 2026.
What were Transmedics Group earnings last quarter?
8T8.XETRA earnings for the last quarter are 0.26 EUR per share, whereas the estimation was 0.51 EUR resulting in a -49.85% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Transmedics Group revenue for the last year?
Transmedics Group revenue for the last year amounts to 525.73M EUR.
What is Transmedics Group net income for the last year?
8T8.XETRA net income for the last year is 163.89M EUR.
In which sector is Transmedics Group located?
Transmedics Group operates in the Other sector.
When did Transmedics Group complete a stock split?
Transmedics Group has not had any recent stock splits.